Cargando…

VH3-53/66-Class RBD-Specific Human Monoclonal Antibody iB20 Displays Cross-Neutralizing Activity against Emerging SARS-CoV-2 Lineages

Immune evasion of SARS-CoV-2 undermines current strategies tocounteract the pandemic, with the efficacy of therapeutic virus-neutralizing monoclonal antibodies (nAbs) being affected the most. In this work, we asked whether two previously identified human cross-neutralizing nAbs, iB14 (class VH1-58)...

Descripción completa

Detalles Bibliográficos
Autores principales: Kulemzin, Sergey V., Sergeeva, Maria V., Baranov, Konstantin O., Gorchakov, Andrey A., Guselnikov, Sergey V., Belovezhets, Tatyana N., Volkova, Olga Yu., Najakshin, Alexander M., Chikaev, Nikolai A., Danilenko, Daria M., Taranin, Alexander V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9224930/
https://www.ncbi.nlm.nih.gov/pubmed/35743680
http://dx.doi.org/10.3390/jpm12060895
_version_ 1784733491677626368
author Kulemzin, Sergey V.
Sergeeva, Maria V.
Baranov, Konstantin O.
Gorchakov, Andrey A.
Guselnikov, Sergey V.
Belovezhets, Tatyana N.
Volkova, Olga Yu.
Najakshin, Alexander M.
Chikaev, Nikolai A.
Danilenko, Daria M.
Taranin, Alexander V.
author_facet Kulemzin, Sergey V.
Sergeeva, Maria V.
Baranov, Konstantin O.
Gorchakov, Andrey A.
Guselnikov, Sergey V.
Belovezhets, Tatyana N.
Volkova, Olga Yu.
Najakshin, Alexander M.
Chikaev, Nikolai A.
Danilenko, Daria M.
Taranin, Alexander V.
author_sort Kulemzin, Sergey V.
collection PubMed
description Immune evasion of SARS-CoV-2 undermines current strategies tocounteract the pandemic, with the efficacy of therapeutic virus-neutralizing monoclonal antibodies (nAbs) being affected the most. In this work, we asked whether two previously identified human cross-neutralizing nAbs, iB14 (class VH1-58) and iB20 (class VH3-53/66), are capable of neutralizing the recently emerged Omicron (BA.1) variant. Both nAbs were found to bind the Omicron RBD with a nanomolar affinity, yet they displayed contrasting functional features. When tested against Omicron, the neutralizing activity of iB14 was reduced 50-fold, whereas iB20 displayed a surprising increase in activity. Thus, iB20 is a unique representative of the VH3-53/66-class of nAbs in terms of breadth of neutralization, which establishes it as a candidate for COVID-19 therapy and prophylactics.
format Online
Article
Text
id pubmed-9224930
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-92249302022-06-24 VH3-53/66-Class RBD-Specific Human Monoclonal Antibody iB20 Displays Cross-Neutralizing Activity against Emerging SARS-CoV-2 Lineages Kulemzin, Sergey V. Sergeeva, Maria V. Baranov, Konstantin O. Gorchakov, Andrey A. Guselnikov, Sergey V. Belovezhets, Tatyana N. Volkova, Olga Yu. Najakshin, Alexander M. Chikaev, Nikolai A. Danilenko, Daria M. Taranin, Alexander V. J Pers Med Article Immune evasion of SARS-CoV-2 undermines current strategies tocounteract the pandemic, with the efficacy of therapeutic virus-neutralizing monoclonal antibodies (nAbs) being affected the most. In this work, we asked whether two previously identified human cross-neutralizing nAbs, iB14 (class VH1-58) and iB20 (class VH3-53/66), are capable of neutralizing the recently emerged Omicron (BA.1) variant. Both nAbs were found to bind the Omicron RBD with a nanomolar affinity, yet they displayed contrasting functional features. When tested against Omicron, the neutralizing activity of iB14 was reduced 50-fold, whereas iB20 displayed a surprising increase in activity. Thus, iB20 is a unique representative of the VH3-53/66-class of nAbs in terms of breadth of neutralization, which establishes it as a candidate for COVID-19 therapy and prophylactics. MDPI 2022-05-29 /pmc/articles/PMC9224930/ /pubmed/35743680 http://dx.doi.org/10.3390/jpm12060895 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Kulemzin, Sergey V.
Sergeeva, Maria V.
Baranov, Konstantin O.
Gorchakov, Andrey A.
Guselnikov, Sergey V.
Belovezhets, Tatyana N.
Volkova, Olga Yu.
Najakshin, Alexander M.
Chikaev, Nikolai A.
Danilenko, Daria M.
Taranin, Alexander V.
VH3-53/66-Class RBD-Specific Human Monoclonal Antibody iB20 Displays Cross-Neutralizing Activity against Emerging SARS-CoV-2 Lineages
title VH3-53/66-Class RBD-Specific Human Monoclonal Antibody iB20 Displays Cross-Neutralizing Activity against Emerging SARS-CoV-2 Lineages
title_full VH3-53/66-Class RBD-Specific Human Monoclonal Antibody iB20 Displays Cross-Neutralizing Activity against Emerging SARS-CoV-2 Lineages
title_fullStr VH3-53/66-Class RBD-Specific Human Monoclonal Antibody iB20 Displays Cross-Neutralizing Activity against Emerging SARS-CoV-2 Lineages
title_full_unstemmed VH3-53/66-Class RBD-Specific Human Monoclonal Antibody iB20 Displays Cross-Neutralizing Activity against Emerging SARS-CoV-2 Lineages
title_short VH3-53/66-Class RBD-Specific Human Monoclonal Antibody iB20 Displays Cross-Neutralizing Activity against Emerging SARS-CoV-2 Lineages
title_sort vh3-53/66-class rbd-specific human monoclonal antibody ib20 displays cross-neutralizing activity against emerging sars-cov-2 lineages
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9224930/
https://www.ncbi.nlm.nih.gov/pubmed/35743680
http://dx.doi.org/10.3390/jpm12060895
work_keys_str_mv AT kulemzinsergeyv vh35366classrbdspecifichumanmonoclonalantibodyib20displayscrossneutralizingactivityagainstemergingsarscov2lineages
AT sergeevamariav vh35366classrbdspecifichumanmonoclonalantibodyib20displayscrossneutralizingactivityagainstemergingsarscov2lineages
AT baranovkonstantino vh35366classrbdspecifichumanmonoclonalantibodyib20displayscrossneutralizingactivityagainstemergingsarscov2lineages
AT gorchakovandreya vh35366classrbdspecifichumanmonoclonalantibodyib20displayscrossneutralizingactivityagainstemergingsarscov2lineages
AT guselnikovsergeyv vh35366classrbdspecifichumanmonoclonalantibodyib20displayscrossneutralizingactivityagainstemergingsarscov2lineages
AT belovezhetstatyanan vh35366classrbdspecifichumanmonoclonalantibodyib20displayscrossneutralizingactivityagainstemergingsarscov2lineages
AT volkovaolgayu vh35366classrbdspecifichumanmonoclonalantibodyib20displayscrossneutralizingactivityagainstemergingsarscov2lineages
AT najakshinalexanderm vh35366classrbdspecifichumanmonoclonalantibodyib20displayscrossneutralizingactivityagainstemergingsarscov2lineages
AT chikaevnikolaia vh35366classrbdspecifichumanmonoclonalantibodyib20displayscrossneutralizingactivityagainstemergingsarscov2lineages
AT danilenkodariam vh35366classrbdspecifichumanmonoclonalantibodyib20displayscrossneutralizingactivityagainstemergingsarscov2lineages
AT taraninalexanderv vh35366classrbdspecifichumanmonoclonalantibodyib20displayscrossneutralizingactivityagainstemergingsarscov2lineages